T1	Sign_symptom 0 19	R everse remodeling
E1	Sign_symptom:T1 
T2	Subject 41 49	patients
T3	Activity 32 37	occur
E2	Activity:T3 
T4	Disease_disorder 80 115	nonischemic dilated cardiomyopathy.
E3	Disease_disorder:T4 
T5	Qualitative_concept 55 76	de novo presentations
R1	MODIFY Arg1:E3 Arg2:T5	
T6	Sign_symptom 116 126	Predictors
E4	Sign_symptom:T6 
T7	Sign_symptom 135 148	recent onset,
E5	Sign_symptom:T7 
T8	Gender 149 159	female sex
T9	Sign_symptom 149 159	female sex
E6	Sign_symptom:T9 
T10	Sign_symptom 161 207	higher left ventricular (LV) ejection fraction
E7	Sign_symptom:T10 
T11	Detailed_description 211 239	echocardiography at baseline
T12	Sign_symptom 241 271	higher systolic blood pressure
E8	Sign_symptom:T12 
T13	Sign_symptom 273 331	QRS width <120 ms (or absence of left bundle branch block)
E9	Sign_symptom:T13 
T14	Sign_symptom 336 356	normal LV dimensions
E10	Sign_symptom:T14 
T15	Biological_attribute 135 356	recent onset, female sex, higher left ventricular (LV) ejection fraction by echocardiography at baseline, higher systolic blood pressure, QRS width <120 ms (or absence of left bundle branch block) and normal LV dimensions
R2	CAUSE Arg1:T15 Arg2:E4	
T16	Medication 1375 1382	digoxin
E11	Medication:T16 
T17	Medication 1384 1394	carvedilol
E12	Medication:T17 
T18	Medication 1400 1409	aldactone
E13	Medication:T18 
T19	Diagnostic_procedure 1215 1238	Cardiac catheterization
E14	Diagnostic_procedure:T19 
T20	Detailed_description 1252 1276	normal coronary arteries
T21	Sign_symptom 1284 1321	LV end-diastolic pressure of 17 mm Hg
E15	Sign_symptom:T21 
T22	Biological_attribute 1284 1321	LV end-diastolic pressure of 17 mm Hg
T23	Subject 1323 1325	He
T24	Activity 1330 1340	discharged
E16	Activity:T24 
T25	Detailed_description 1341 1345	home
R3	MODIFY Arg1:T25 Arg2:E16	
T26	Sign_symptom 370 387	increased LV size
E17	Sign_symptom:T26 
T27	Qualitative_concept 405 427	poor prognostic marker
R4	MODIFY Arg1:T22 Arg2:E14	
T28	Medication 1443 1482	angiotensin-converting enzyme inhibitor
E18	Medication:T28 
T29	Medication 1487 1518	angiotensin receptor antagonist
E19	Medication:T29 
T30	Administration 1523 1533	prescribed
R5	MODIFY Arg1:E18 Arg2:T30	
R6	MODIFY Arg1:E19 Arg2:T30	
T31	Time 1534 1546	at that time
E20	Time:T31 
R7	CO-OCCURANCE Arg1:E20 Arg2:E18	
T32	Subject 1552 1559	patient
T33	Activity 1564 1568	lost
E21	Activity:T33 
T34	Activity 1573 1581	ollow-up
E22	Activity:T34 
T35	Time 1636 1649	3 years later
E23	Time:T35 
T36	Duration 1636 1649	3 years later
E24	Duration:T36 
R8	MODIFY Arg1:E24 Arg2:T32	
T37	Sign_symptom 1665 1677	palpitations
E25	Sign_symptom:T37 
T38	Activity 1665 1677	palpitations
E26	Activity:T38 
T39	Biological_attribute 1665 1677	palpitations
R9	CO-OCCURANCE Arg1:T39 Arg2:E24	
T40	Subject 633 640	patient
T41	Age 644 655	45-year-old
T42	Ethnicity 656 661	black
T43	Gender 662 665	man
T44	Diagnostic_procedure 681 690	diagnosed
E27	Diagnostic_procedure:T44 
T45	Disease_disorder 696 718	dilated cardiomyopathy
E28	Disease_disorder:T45 
T46	Activity 728 737	admission
E29	Activity:T46 
T47	Sign_symptom 767 784	sinus tachycardia
E30	Sign_symptom:T47 
T48	Sign_symptom 786 793	dyspnea
E31	Sign_symptom:T48 
T49	Sign_symptom 799 814	volume overload
E32	Sign_symptom:T49 
R10	CAUSE Arg1:E30 Arg2:E28	
R11	CAUSE Arg1:E31 Arg2:E28	
R12	CAUSE Arg1:E32 Arg2:E28	
R13	BEFORE Arg1:E28 Arg2:E27	
R14	CAUSE Arg1:E28 Arg2:E27	
T50	Qualitative_concept 671 680	initially
R15	MODIFY Arg1:T50 Arg2:E27	
T51	Subject 816 818	He
T52	Activity 819 825	denied
E33	Activity:T52 
T53	Other_entity 826 833	alcohol
T54	Other_entity 835 839	drug
T55	Other_entity 844 853	stimulant
T56	Activity 854 857	use
E34	Activity:T56 
R16	MODIFY Arg1:T53 Arg2:E34	
R17	MODIFY Arg1:T53 Arg2:E34	
R18	MODIFY Arg1:T54 Arg2:E34	
T57	Qualitative_concept 866 878	risk factors
T58	Disease_disorder 883 912	Human Immunodeficiency Virus;
E35	Disease_disorder:T58 
R19	MODIFY Arg1:T57 Arg2:E35	
T59	Qualitative_concept 863 865	no
R20	MODIFY Arg1:T59 Arg2:T57	
T60	Qualitative_concept 921 923	no
T61	Detailed_description 925 938	amily history
R21	MODIFY Arg1:T60 Arg2:T61	
T62	Disease_disorder 942 956	cardiomyopathy
E36	Disease_disorder:T62 
R22	CO-OCCURANCE Arg1:E36 Arg2:T60	
T63	Time 962 969	initial
E37	Time:T63 
T64	Diagnostic_procedure 970 998	transthoracic echocardiogram
E38	Diagnostic_procedure:T64 
T65	Activity 999 1007	revealed
E39	Activity:T65 
T66	Volume 1011 1028	ejection fraction
T67	Volume 1032 1035	21%
R23	CO-OCCURANCE Arg1:T66 Arg2:T67	
T68	Qualitative_concept 1041 1047	severe
T69	Disease_disorder 1048 1068	mitral regurgitation
E40	Disease_disorder:T69 
T70	Sign_symptom 1048 1068	mitral regurgitation
E41	Sign_symptom:T70 
T71	Biological_structure 1073 1088	LV end-systolic
T72	Biological_structure 1093 1117	end-diastolic dimensions
T73	Distance 1119 1125	6.3 cm
T74	Distance 1130 1136	7.3 cm
R24	MODIFY Arg1:T74 Arg2:T72	
R25	MODIFY Arg1:T73 Arg2:T71	
T75	Biological_attribute 1153 1184	Brain natriuretic peptide (BNP)
T76	Activity 1189 1197	recorded
E42	Activity:T76 
T77	Quantitative_concept 1201 1210	368 pg/mL
R26	MODIFY Arg1:T77 Arg2:E42	
T78	Therapeutic_procedure 1349 1364	medical therapy
E43	Therapeutic_procedure:T78 
R27	BEFORE Arg1:E43 Arg2:E11	
R28	BEFORE Arg1:E43 Arg2:E12	
R29	BEFORE Arg1:E43 Arg2:E13	
